PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation
clinical trial of docetaxel and cisplatin combination chemotherapy with and without
panitumumab in the first-line treatment of subjects with metastatic or recurrent head and
neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail
the chemotherapy only arm. This study will be conducted in the United States. Approximately
150 subjects with histologically or cytologically confirmed metastatic and/or recurrent
SCCHN.